The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 4, 2006, Pages 444-450

  Williams, Ryan ^a   Baker, Amanda F ^b   Ihle, Nathan T ^a   Winkler, Ashley R ^b   Kirkpatrick, Lynn ^c   Powis, Garth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Biomira Inc   (Canada)

Author keywords

Hair; Phospho Akt; PtIns 3 kinase activity; Skin

Indexed keywords

3 DEOXYPHOSPHATIDYLMYOINOSITOL 1 (2 METHOXY 3 OCTADECYLOXYPROPYL HYDROGEN PHOSPHATE); 4 DIALLYLAMINOMETHYLENE 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ESTER; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PX 316; PX 866; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER CELL CULTURE; CANCER MODEL; CELL STRAIN HT29; CELL STRAIN MCF 7; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; EVALUATION; FEMALE; HAIR ANALYSIS; HAIR ROOT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION; SKIN; TUMOR XENOGRAFT; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TUMOR; ENZYME INHIBITORS; GONANES; HAIR; HUMANS; INOSITOL PHOSPHATES; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; SIGNAL TRANSDUCTION; SKIN;

EID: 33744786631     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0190-0     Document Type: Article

References (30)

1. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro J, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson R, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition, J Clin Oncol 20:110-124
2. Alessi DR, Cohen P (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genet Develop 8:55-62
3. Bates S, Vousden K (1999) Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28-37
4. Berrie C P (2001) Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opin Investig Drugs 10:1085-1098
5. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245
6. Cantley LC (2000) The phosphoinositide 3-kinase pathway. Science 296:1655-1657
7. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321
8. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241
9. Engleman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102:3788-3793
10. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI-3K/Akt pathway for cancer drug discovery. Nature Rev Drug Discov 4:987-1004
11. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick DL, Powis G (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Thera 3:1-10
12. Ihle N, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G (2005) The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4:1349-1357
13. Jost M., Kari C, Rodeck U (2000) The EGF receptor: an essential regulator of multiple epidermal functions. Eur J Dermatol 10:505-510
14. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E et al (2002) Phosphoinositide-3-kinase gamma is an essential amplifier of mast cell function. Immunity 16:441-451
15. Lee M, Seo C, Kim S, Yang H, Lee H, Choi J, Moon K, Koh J (2004) Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD 1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 84:23-26
16. Malik S, Siu L, Rowinsky E, DeGraffenried L, Hammond L, Rizzo J, Bacus S, Brattain M, Kreisberg J, Hidalgo M (2003) Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9:2478-2486
17. Meier R, Alessi Dr, Cron P, Andjelkovic M, Hemmings BA (1997) Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B. J Biol Chem 272:30491-30497
18. Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G (2003) Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther 2:389-399
19. Meuillet E, Ihle N, Baker A, Gard J, Stamper C, Williams R, Coon A, Mahadevan D, George B, Kirkpatrick D, Powis G (2004) In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 14:513-527
20. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt Signaling pathway in human malignancy. Cell Signal 14:381-395
21. Peng X-D, Xu P-Z, Chen M-L, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen W, Crawford S, Coleman K, Hay N (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Develop 17:1352-1365
22. Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10:6759-6763
23. Sjölander A, Yamamoto K, Huber BE, Lapetina EG (1991) Association of p21ras with phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 88:7908-7947
24. Stein RC (2001) Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8:237-248
25. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epi dermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22:3080-3090
26. Taylor G, Lehrer M., Jensen P (2000) Involvement of follicular stem cells in forming not only the follicle but also the epidermis. Cell 102:451-461
27. Traicoff JL, Baibakov G, Biesecker G, Richardson F, Ramesh A, Galperin MM, Iwata KK, Knezevic V (2005) Novel application of layered expression scanning for proteomic profiling of plucked hair follicles. Dermatology 210(4):275-278
28. Van Haesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide3-kinases. Exp Cell Res 253:239-254
29. Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G (2004) Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org Biomol Chem 2:1911-1920
30. Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signaling-which way to target? Trends Pharmacol Sci 24:366-369